Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Whitehawk Therapeutics (WHWK) Free Cash Flow (2018 - 2025)

Whitehawk Therapeutics (WHWK) has disclosed Free Cash Flow for 8 consecutive years, with -$17.8 million as the latest value for Q4 2025.

  • Quarterly Free Cash Flow fell 16.71% to -$17.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$98.0 million through Dec 2025, down 60.1% year-over-year, with the annual reading at -$98.0 million for FY2025, 60.1% down from the prior year.
  • Free Cash Flow for Q4 2025 was -$17.8 million at Whitehawk Therapeutics, down from -$15.4 million in the prior quarter.
  • The five-year high for Free Cash Flow was $10.6 million in Q1 2021, with the low at -$52.4 million in Q2 2025.
  • Average Free Cash Flow over 5 years is -$14.8 million, with a median of -$14.9 million recorded in 2023.
  • The sharpest move saw Free Cash Flow surged 368.11% in 2021, then plummeted 440.38% in 2025.
  • Over 5 years, Free Cash Flow stood at -$12.5 million in 2021, then increased by 8.71% to -$11.4 million in 2022, then grew by 8.15% to -$10.5 million in 2023, then crashed by 45.69% to -$15.2 million in 2024, then decreased by 16.71% to -$17.8 million in 2025.
  • According to Business Quant data, Free Cash Flow over the past three periods came in at -$17.8 million, -$15.4 million, and -$52.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.